On January 11, the centralized procurement of oral implant systems at the provincial level opened in Chengdu. According to the article on China Medical Insurance, the only media platform affiliated to the National Medical Insurance Administration, this is the first attempt to expand the centralized procurement of high-value consumables from the medical insurance field to the non-medical insurance field. .
At around 12:30 noon, the proposed selection results of the centralized procurement were announced at the bid opening site.
A total of 40 products are to be selected this time, including 20 products in Group A and 20 products in Group B, involving domestic and foreign companies such as Straumann, Nobel Bio, Weigao, and Bioconte.
Judging from the list of results to be selected, Hangzhou Minsheng Lide Medical Technology Co., Ltd.’s grade 4 pure titanium product system in Group B reported the lowest price of 548 yuan, compared with the highest effective declared price of 2380 yuan per set. A decrease of about 77%, ranking first in the selection rules of its bidding unit.
The Paper reporter noticed that after hearing the price of 548 yuan, some company representatives exclaimed: "It's incredible."
Judging from the first-year procurement demand and the first-year intentional procurement volume announced in the previous centralized procurement documents for dental implants, the procurement demand and intentions of Aotai, Denteng, Straumann, Nobel Bio, and R&B Dental in Group A The purchase volume ranks among the top five, all of which are above 100,000 sets.
On-site quotations at the bid opening show that the quotation of Aotaitai’s four-grade pure titanium product system is 771 yuan, a decrease of about 68% compared with the highest effective declared price; A drop of about 51%; the price of Nobel Bio’s four-grade pure titanium product system is 1,855 yuan, a drop of about 22% from the highest effective declared price.
The above-mentioned enterprises all appear in the list of candidates to be selected.
Straumann, a well-known dental equipment company from Switzerland, also participated in the on-site quotation. Its titanium alloy product system quotation was 3,517 yuan, which exceeded the highest effective declared price of 2,380 yuan, and did not get the proposed selection result.
However, the company's four-grade pure titanium product system quotation was 1,855 yuan, a drop of about 22%, and it was qualified for the proposed selection, ranking 13th in the bidding unit's proposed selection rules.
In this collective procurement, some companies also made quotations at the highest effective declared price of 2380 yuan. For example, the quotation of Changzhou Bioconte’s titanium alloy product system in Group A was 2380 yuan, which did not enter the list of proposed selection results, while the company’s other four The price of the high-grade pure titanium product system is 630 yuan, which is more than 74% lower than the highest effective declared price, and the first place won the bid.
According to the Announcement (No. 2) of Centralized Procurement of Interprovincial Alliance of Dental Implant System, the centralized procurement of dental implant system consists of one implant, one prosthetic abutment, and one accessory package each. Body materials are divided into two product system categories: four-grade pure titanium implant product system and titanium alloy implant product system, and specific requirements are made for each component.
The highest effective declared price of the grade 4 pure titanium implant product system and the titanium alloy implant product system is 2380 yuan/set, and the centralized procurement cycle is 3 years.
Judging from the announcement, the first-year intended purchase volume of each product system category is based on 90% of the first-year purchase demand of each product system submitted by each medical institution participating in this centralized procurement (if there is a non-integer number, round up whole to ones) are accumulated.
Among them, the first-year purchase demand of the four-grade pure titanium implant product system is 2,494,956 sets, and the first-year intended purchase amount is 2,253,818 sets; the first-year purchase demand of the titanium alloy implant product system is 375,087 sets, and the first-year intended purchase amount is 339,335 sets set.
Based on this calculation, the total annual demand for the above-mentioned products exceeds 2.8 million sets, and the intended purchase volume in the first year exceeds 2.59 million sets.